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Objective. To estimate level of adherence to oral calcium and vitamin D supplementation as well as bisphosphonate amongst
patients with PMR and GCA treated with glucocorticoids.Method. A total of 138 patients with the diagnosis of PMR and/or GCA
registered in our department in December 2013. In this cross-sectional study we interviewed all the patients to measure level of
adherence to calcium and vitamin D, as well as bisphosphonates. Results. Out of the 118 included patients, 88.9% of them were
adherent to their prescription. Only 2 patients (1.7%) did not take calcium and vitamin D at all and 10 patients (8.5%) took their
medication infrequently, 9 and 1 out of 10 patients took the medication 50–100% of the time and less than 50% of the prescribed
dose, respectively. Sixty-one patients received additional treatment with bisphosphonate and 96.6% were adherent to this therapy.
The remaining 3.4% of the patients did not take the medication at all. Forgetfulness, adverse side effects, and lack of understanding
of treatment benefits were the most significant causes for nonadherence to calcium and vitamin D. Conclusions. Contrary to what
we expected this study found that adherence to osteoporosis preventive medication in patients with PMR and GCA was high.
1. Introduction
Polymyalgia rheumatica (PMR) and Giant Cell Arteritis
(GCA) are common inflammatory conditions that almost
exclusively affect patients older than 50 years. These con-
ditions often occur together. 18–26% of patients with PMR
have GCA while 27–53% of patients with GCA have also
PMR at the same time. PMR primarily presents with stiffness
and pain in the proximal muscle including neck, shoulders,
buttocks, and thighs that causes severe disability without
suitable treatment. GCA is the most common vasculitis in
older persons and involves medium to large artery. It can
result in blindness if not diagnosed and treated immedi-
ately. Older age, female sex, and northern European descent
are the most important risk factors for both conditions.
Diagnosis is based on clinical and laboratory evaluations.
Temporal artery biopsy should be performed in GCA cases
[1, 2], patients with cranial symptoms, and when either
diagnosis is suspected as proposed by the National Danish
Guidelines [3]. Glucocorticoids (GC) are the mainstay of
treatment in patients with PMR and GCA [4].
One of the important complications amongst PMR and
GCA patients who received GC in the long term (>3 months)
is glucocorticoid-induced osteoporosis (GIO) that leads to
an increased risk of fracture. This is due to impairment
of calcium absorption in the intestine and reabsorption
in the tubular system of kidneys. Inflammation, reduced
mobility, and older age which characterize this group of
patients further contribute to an increased risk [2, 4, 5].
According to several studies bisphosphonates, vitamin D,
and calcium are effective for preventing GIO [2, 4, 6–10].
The American College of Rheumatology suggests use of
1200–1500mg/day calciumplus 800–1000U/day vitaminD to
prevent GIO. Furthermore lifestyle modification and regular
weight bearing exercise can improve outcomes [5].
To prevent loss of bonemass, all of our patients with PMR
and GCA were prescribed calcium and vitamin D supple-
ments and depending on the bone density, evaluated with
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a DXA-scan (dual energy X-ray absorptiometry), received
additional treatment with bisphosphonate (if 𝑇-score <
−1). Previous studies showed that the level of adherence
to osteoporosis preventive medications is poor, leading to
increased risk of fracture and hospitalization [11–16]. Several
factors may contribute to nonadherence including concern
of potential side effects, inconvenience, cost of medication,
or lack of understanding of the benefits of therapy [12, 16,
17]. The aim of the current study is to estimate adherence
to oral calcium and vitamin D supplementation as well
as bisphosphonate amongst patients with PMR and GCA
receiving long-term treatment with GC and identify factors
associated with nonadherence. In addition we evaluated
patients’ adherence when responsible physician referred the
patients to a DXA-scan.
2. Method
We used patient interview to measure adherence to pre-
scribed medication in a cross-sectional study. All patients
with the diagnosis of PMR and/or GCA diagnosed according
to theDanish national guideline, registered in the department
of rheumatology, Svendborg hospital, in December 2013 were
identified and contacted by phone and were asked if they
wanted to participate in the study. They were requested to
answer a set of previously defined questions (see Adher-
ence Interview Form) about medication and adherence. All
telephone interviews were performed by registered physi-
cians or nurses who the patients knew. For each patient
demographic data including age, sex, and smoking status
were collected. Information on GC treatment, calcium, and
vitamin D supplements and bisphosphonate was obtained
using patients’ records. Patients’ records were also evaluated
individually for previous laboratory tests, imaging studies
including DXA-scan, positron emission tomography, and
biopsy of temporal artery to ensure accurate diagnosis and
if relevant diagnostic tests were performed. A patient was
considered to be adherent if medication was taken as pre-
scribed in the records. Finally the patients were asked about
the reasons for nonadherence if they had discontinued the
medications. The study was approved by the Danish Data
Protection Agency (file number 2008-58-0035, 14/4017). All
analyses were performed using SPSS version 22.0.
Adherence Interview Form
(1) Patient code number:
(2) Age:
(3) Diagnose:
PMR
GCA
(4) Smoking status
Yes
No
(5) Do you take prednisolone tablet daily:
Yes
No
(6) Prednisolone Dosage:
(7) Are you prescribed calcium and vitamin D supple-
ments with start of prednisolone:
Yes
No
(8) Do you always remember to take your calcium,
vitamin D supplements?
100%
50–100%
<50%
Never
(9) If yes, which type of calcium and vitamin D supple-
ments do you take?
(10) Number of calcium and vitamin D tablets per day:
(11) If no, why don’t you take your medication?
Fear of side effects
I don’t take much medication
I don’t have more pills
Side effects (nausea, constipation)
I don’t think it is necessary
A doctor or nurse have told me not to eat it
I can not afford it
I don’t know
Others
(12) Do you eat dairy products or fish daily:
Yes
No
(13) Do you take vitamin supplements
Yes
No
(14) Have you previously done DXA-scan:
Yes
No
(15) If yes, date/year of previous DXA-scan:
(16) Do you take prophylactic osteoporosismedication for
example Fosamax, Alendronate, Bonviva, Aclasta:
Yes
No
(17) If yes, name of your prophylactic osteoporosis medi-
cation:
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(18) Do you take always your preventive medication:
100%
50–100%
<50%
Never
(19) Why do not you take your preventive medication:
Fear of side effects
I don’t take much medication
I don’t have more pills
Side effects
I can not afford it
I don’t think it is necessary
I don’t know
Others
3. Results
We identified 138 patients with PMR and/or GCA. Twelve
patients subsequently received an alternative diagnosis, in
most cases Rheumatoid Arthritis, three patients could not be
reached on the phone, two did not want to participate in the
study, and three were not contacted, because it was clear from
the records that theywere demented. In total 118 patients were
included (Figure 1).
The mean age of patients was 73 ± 8 years. Sixty percent
were female and 15% of patients were smoker. Out of 118
patients 85 patients were diagnosedwith PMR and 33 patients
were diagnosed with GCA.Themean of prednisolone dosage
was 10.5 ± 9.4mg with a range between 2.5 and 50mg. 117
patients (99.2%) had prescribed calcium and vitamin D and
88.9% of them were adherent to their prescription. Only 2
patients (1.7%) did not take calcium and vitamin D at all,
and 10 patients (8.5%) took their medication infrequently, 9
and 1 out of 10 patients took the medication 50–100% of the
time and less than 50% of the prescribed dose, respectively
(Figure 2).
The reasons for incomplete adherence were forgetfulness
in 42.9% of patients, 35.7% of patients could not explain
the reason, one patient did not want to eat so many pills,
one patient claimed of side effects, and one patient thought
prophylactic calcium and vitamin D supplement was unnec-
essary (Figure 3).
From the 118 patients 113 (95.7%) were referred to a DXA-
scan, of which 103 had been scanned and 10 were awaiting
scan results. 5 patients were not referred. All patients who
were referred for DXA-scan were involved in the study.
In 61 patients bisphosphonate was additionally prescribed
and 96.6% were adherent to this therapy. The remaining
3.4% of the patients did not take the medication at all
(Figure 2). Two patients discontinued the medication after
receiving advice from their private physician. Nonadherence
to bisphosphonate was in all cases due to gastrointestinal side
effects.
3 patients were
excluded due to
138 patients in total 
were included
12 patients received
 an alternative
2 patients did not
want to participate
3 patients could not
 be reached on the
 diagnosis
dementia  phone
N = 118
patients
Figure 1: Patients included in the study.
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Figure 2: Level of adherence to Ca, vitamin D supplements, and
bisphosphonates amongst PMR/GCA patients.
4. Discussion
Glucocorticoid-induced osteoporosis is an important side
effect of treatment with GC amongst patients with PMR and
GCA.The frequency of osteoporosis ranges between 14.9 and
85% in patients. Risk of fracture in patients who received
long-term GC is about 33–50% which depends on daily and
cumulative dose [18]. Low body mass index, smoking, intake
of more than two standard alcoholic drinks per day, and
history of hip fracture in parents are related with higher risk
for GIO [5]. As a result treatment with calcium and vitaminD
should be started to prevent bone loss [4]. Bisphosphonates
are generally indicated in patients receiving long-term GCs
[5].
As in any medical treatment, adherence to prescribed
medication is an important factor to achieve best outcome.
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Figure 3: The most important causes of nonadherence amongst
PMR/GCA patients.
Results of recent studies showed that adherence to osteoporo-
sis preventivemedications is relatively poor [11–13]. However,
there has been some controversy regarding adherence to
osteoporosis preventive medications. A cross-sectional study
by Castelo-Branco et al. [11] in Spain showed that out of 7888
patients aged 45 or over, who received calcium and vitamin
D supplementation, only 31.2% were adherent. Fatigue due
to long-term therapy was the main reason for nonadherence
amongst the patients. Another study by Rossini et al. [15]
carried out on 9851 postmenopausal women revealed that
adherence to treatment with osteoporosis preventive med-
ications was poor. Additionally, the authors concluded that
the most important reasons of nonadherence are fear of side
effects and lack of motivation. On the contrary, recent study
by Tafaro et al. [19] showed high adherence to osteoporosis
preventive medications if therapies less than 30 days were
excluded.Out of 6930 patientswhowere included in the study
43.8% were adherent to the treatment. The most frequent
reasons of nonadherence were included side effects and
misinformation given by the physician.
Contrary to what we expected this study found that
adherence to preventative osteoporosis medications in
patients with PMR and GCA was high and the most frequent
causes for nonadherence were forgetfulness and side effects.
One of the reasons of our patients’ high adherence to the
osteoporosis preventive medications is patients’ awareness
of GCs side effects and osteoporosis. This is due to the
fact that all physicians are responsible to inform patients
about the side effects of GC treatment. In the same way
responsible physicians and nurses are asked to update the
patient medical status at each visit and specifically ask
whether the patients prescribed osteoporosis preventive
medication while they receive GC treatment. When patients
pick up their prescribed GC from the drugstore they will also
be reminded that they should take calcium and vitamin D. In
addition the important patient association, the Osteoporosis
Associations in Denmark with 24 local subdivisions, gives
useful information about osteoporosis to the patients who
are at risk of osteoporosis as well as entire population. This
is in line with previous findings [14, 16, 18], suggesting
that the deficit in patient awareness is related with low
adherence and physicians support is an important factor to
achieve better adherence. On the other hand, most of our
patients (96%) are referred to carry out DXA-scan which
stressed the importance of treatment. Another important
factor for the high adherence in our patient group could be
that PMR/GCA can be very painful conditions, where the
prescribed prednisolone treatment causes rapid freedom
from symptoms. This can underpin confidence in the
physician’s treatment and why adherence to the additional
prophylactic treatment might be higher.
The limitation of our study was that there was no way
to control patients’ answers as well as medications intake.
Moreover the accuracy of results was dependent on patients’
memory to report their adherence level retrospectively. We
cannot rule out information bias, as there will probably be
a tendency for the patients to provide what they believe to
be socially accepted answers rather than the truth, especially
with regard to behavioral aspects and health conditions
associated with taboos [20]. In our situation a taboomight be
the fact that the patient had not followed the doctor’s advice.
Since the patients were asked the name of the formulations
and since the patients in a friendly tone were told that lack
of adherence is a common and understandable state, we
believe that we have predominantly received correct answers
from our patients. We think that our concept of giving
thorough information concerning the side effects ofGC to the
patients at each visit in the clinic followed by a prescription
of DXA-scan is advisable for all departments to increase
patients’ adherence. We also think that our patient popu-
lation with well characterized and initially painful diseases
were more motivated for prophylaxis than otherwise healthy
postmenopausal osteoporotic patients, where the adherence
is described to be low [11–13]. A possible way for evaluation
whether the patients pick up the medicine at the pharmacies
might be to check this on the electronic journals medication
module, which is possible, but it requires an additional
permission from the Danish Data Protection Agency as well
as from the patient. There is probably little doubt that this
would astonish patients much and give them a feeling that
we do not trust them, which would make cooperation with
the patients difficult in the future. More studies in this field
are needed to confirm our results, but we see already a
problem in a prospective design, because this cannot be done
without patients knowing it will be checked, if they collect
the medication, thereby inducing a relative risk for another
information bias.
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